C-Reactive Protein and Covid-19 Severity: A Systematic Review
- PMID: 34856793
C-Reactive Protein and Covid-19 Severity: A Systematic Review
Abstract
Background: COVID-19 clinical course has been quite unpredictable and efforts have been made to identify reliable markers that will help in early disease progression, prognosis and severity detection. Objective: This study thus aimed to provide evidence that will guide clinical management by reviewing studies that assessed CRP concentration and COVID-19 severity/outcome.
Methods: Three electronic databases, PubMed/Medline, Google Scholar, and JSTOR were searched to identify studies available online as at 1st September 2020 which assessed COVID-19 clinical outcome and CRP concentration. The search strategy involved words combination like "C-reactive protein" OR "inflammatory markers" OR "acute phase reactants" and "coronavirus 2019" OR ''COVID-19" OR "2019-nCoV" OR "SARS-CoV-2".
Results: Sixty-one articles were systematically reviewed out of 812 studies identified after duplicates were removed. The 61 studies comprised 13,891 COVID-19 patients made of 7,840 (56.4%) males and 6,051 (43.6%) females. All the papers revised were observational studies except one case-control and they cut across fifteen countries. The result of the review demonstrated that the severe cases had higher levels of C - reactive protein when compared to the mild cases in all the studies (100%). The increase in C-reactive protein was statistically significant in 78.7% of the cases.
Conclusion: High levels of CRP are associated with COVID-19 severity.
Highlights: Severe cases of COVID-19 is characterized with higher CRP levels. COVID-19 cases should be screened regularly for CRP to monitor severity.
Contexte: L'évolution clinique du COVID-19 a été assez imprévisible et des efforts ont été faits pour identifier des marqueurs fiables qui aideront à la progression précoce de la maladie, au pronostic et à la détection de la gravité. Objectif : Cette étude visait donc à fournir des preuves qui guideront la gestion clinique en passant en revue les études qui ont évalué la concentration de CRP et la gravité/l'issue du COVID-19.
Méthodes: Trois bases de données électroniques, PubMed/Medline, Google Scholar et JSTOR, ont été consultées pour identifier les études disponibles en ligne au 1er septembre 2020 qui évaluaient le résultat clinique du COVID-19 et la concentration de CRP. La stratégie de recherche comportait des combinaisons de mots comme "protéine Créactive" OU "marqueurs inflammatoires" OU "réactifs de phase aiguë" et "coronavirus 2019" OU "COVID-19" OU "2019-nCoV" OU "SARS-CoV-2".
Résultats: Soixante et un articles ont été systématiquement examinés sur les 812 études identifiées après suppression des doublons. Les 61 études comprenaient 13 891 patients atteints de COVID-19, dont 7 840 (56,4 %) hommes et 6 051 (43,6 %) femmes. Tous les articles examinés étaient des études d'observation, à l'exception d'un cas-témoin, et ils couvraient quinze pays. Le résultat de l'examen a démontré que les cas graves avaient des niveaux plus élevés de protéine C-réactive par rapport aux cas légers dans toutes les études (100%). L'augmentation de la protéine C-réactive était statistiquement significative dans 78,7% des cas.
Conclusion: Des niveaux élevés de CRP sont associés à la sévérité du COVID-19.
Mots clés: Protéine C-réactive, COVID-19, SRAS-COV-2 et Coronavirus.
Points forts: Les cas graves de COVID-19 sont caractérisés par des niveaux de CRP plus élevés. · Les cas de COVID-19 doivent faire l'objet d'un dépistage régulier de la CRP afin de surveiller la gravité de la maladie.
Keywords: C-reactive protein; COVID-19; SARS-COV-2 andCoronavirus.
Copyright © 2021 by West African Journal of Medicine.
Conflict of interest statement
The Authors declare that no competing interest exists
Similar articles
-
Clinical characteristics of coronavirus disease 2019 (COVID-19) in patients out of Wuhan from China: a case control study.BMC Infect Dis. 2021 Feb 24;21(1):207. doi: 10.1186/s12879-021-05897-z. BMC Infect Dis. 2021. PMID: 33627079 Free PMC article.
-
The laboratory findings and different COVID-19 severities: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2021 Mar 16;20(1):17. doi: 10.1186/s12941-021-00420-3. Ann Clin Microbiol Antimicrob. 2021. PMID: 33726761 Free PMC article.
-
Expressions of SAA, CRP, and FERR in different severities of COVID-19.Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11386-11394. doi: 10.26355/eurrev_202011_23631. Eur Rev Med Pharmacol Sci. 2020. PMID: 33215460
-
Association between serum inflammatory parameters and the disease severity in COVID-19 patients.J Clin Lab Anal. 2022 Jan;36(1):e24162. doi: 10.1002/jcla.24162. Epub 2021 Dec 7. J Clin Lab Anal. 2022. PMID: 34874079 Free PMC article.
-
Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis.Int J Environ Res Public Health. 2020 Jul 13;17(14):5026. doi: 10.3390/ijerph17145026. Int J Environ Res Public Health. 2020. PMID: 32668763 Free PMC article.
Cited by
-
COVID19 biomarkers: What did we learn from systematic reviews?Front Cell Infect Microbiol. 2022 Dec 13;12:1038908. doi: 10.3389/fcimb.2022.1038908. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36583110 Free PMC article. Review.
-
C-Reactive Protein (CRP): A poor prognostic biomarker in COVID-19.Front Immunol. 2022 Nov 14;13:1040024. doi: 10.3389/fimmu.2022.1040024. eCollection 2022. Front Immunol. 2022. PMID: 36451818 Free PMC article.
-
Correlation between the severity of COVID-19 infection and the presence of oropharyngeal candidiasis: a cross-sectional study in Al-Diwaniyah Hospital, Iraq.Pan Afr Med J. 2025 Jan 13;50:25. doi: 10.11604/pamj.2025.50.25.43995. eCollection 2025. Pan Afr Med J. 2025. PMID: 40322330 Free PMC article.
-
Adipokines as Diagnostic and Prognostic Markers for the Severity of COVID-19.Biomedicines. 2023 Apr 27;11(5):1302. doi: 10.3390/biomedicines11051302. Biomedicines. 2023. PMID: 37238973 Free PMC article. Review.
-
Exploring the Relationship between Plasma Adiponectin, Gender, and Underlying Diseases in Severe Illness.Biomedicines. 2023 Dec 12;11(12):3287. doi: 10.3390/biomedicines11123287. Biomedicines. 2023. PMID: 38137508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous